Business Context and Reporting Period
Company: Chemed Corporation (CHEMED CORP)
Filing Type: Form 8-K (Current Report)
Date of Report: October 11, 2002
Event: Disposition of Assets (Sale of Patient Care Inc.)
On October 11, 2002, Chemed Corporation sold its wholly owned subsidiary, Patient Care Inc. (and its subsidiary National Home Care Inc.), to an investor group led by PCI Holding Corp. Patient Care provided home-healthcare services primarily in the New York-New Jersey-Connecticut area.
Key Financial Metrics and Transaction Details
Transaction Consideration:
- Cash Proceeds: $57.5 million total ($52.0 million immediate; $5.0 million in escrow).
- Debt Instrument: $12.5 million senior subordinated note receivable (due Oct 11, 2007; interest rates ranging from 7.5% to 9.5%).
- Equity Instrument: Warrant to purchase 2% of PCI-H outstanding stock (estimated fair value: $1.4 million).
Pro Forma Financial Impact (as of June 30, 2002):
- Total Assets: Reduced from $393.9 million (historical) to $386.1 million (pro forma).
- Current Assets: Increased net cash position significantly; total current assets rose from $101.2 million to $115.4 million due to proceeds.
- Goodwill: Reduced by $30.7 million to $131.2 million.
- Long-term Debt: Remained at $55.8 million (historical), though management intends to use proceeds to retire borrowings.
Material Changes Versus Prior Periods
The filing presents unaudited pro forma financial statements assuming the disposition occurred at the beginning of the periods presented. Key changes include:
- Revenue Reduction: Pro forma service revenues for the year ended Dec 31, 2001, decreased from $477.1 million to $337.9 million.
- Expense Reduction: Total costs and expenses for the year ended Dec 31, 2001, decreased from $484.4 million to $346.7 million.
- Operating Loss: Pro forma operating loss for 2001 widened slightly from $(7.3) million to $(8.8) million due to the removal of Patient Care's operating income.
- Net Income Impact (6 Months Ended June 30, 2002): Pro forma net income from continuing operations decreased from $9.2 million (historical) to $7.6 million (pro forma), primarily due to the removal of Patient Care's earnings, partially offset by interest income on the note receivable.
Guidance, Outlook, and Management Commentary
Use of Proceeds: The Company intends to use a portion of the cash proceeds to retire borrowings under its revolving credit agreement with Bank One, N.A. (which had $25 million outstanding as of Sept 30, 1997). The balance will be used for future acquisitions and general corporate purposes.
Management Commentary: The transaction was executed with an investor group including Schroder Ventures Life Sciences Group, Oak Investment Partners, Prospect Partners, and Salix Ventures. There are no material relationships between the buyer and Chemed's directors or officers.
Risks and Contingencies: $5 million of the cash proceeds is held in escrow pending the settlement of specified contingencies. The pro forma financial statements are for illustrative purposes only and do not necessarily indicate future results.
Investor Verification Checklist
- Escrow Release: Monitor the status of the $5 million held in escrow and the conditions required for its release.
- Debt Repayment: Verify the actual amount of revolving credit debt retired using the proceeds.
- Note Receivable Performance: Track the $12.5 million note receivable for timely interest payments and principal repayment at maturity in 2007.
- Warrant Valuation: Assess the potential value of the 2% warrant in PCI-H based on the performance of the acquired entity.
- Future Acquisitions: Review subsequent filings for details on how the remaining cash is deployed for new acquisitions.